Skip to content

Crinetics Pharmaceuticals CRNX Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

Enliven Therapeutics logo
Enliven TherapeuticsELVN
-$26.5K-864%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$59.33M
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Cash & equivalents$115.1M+20.1%
Total debt$47.9M-5.8%
Total equity$1.3B+2.1%
Total assets$1.4B+2.9%

Cash flow

See full
Operating cash flow-$124.7M-41.0%
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation

See full
Market cap$3.79B+21.9%

Profitability

See full
Gross margin150%-15.6pp
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0.0×
Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnSaleOfPropertyPlantEquipment.

The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Crinetics Pharmaceuticals's gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Crinetics Pharmaceuticals's gain/loss on asset sales?
Crinetics Pharmaceuticals (CRNX) reported gain/loss on asset sales of -$20K in Q1 2026.
How has Crinetics Pharmaceuticals's gain/loss on asset sales changed year-over-year?
Crinetics Pharmaceuticals's gain/loss on asset sales decreased by 5.3% year-over-year, from -$19K to -$20K.
What does gain/loss on asset sales mean?
Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.